Table 2.

Clinical parameters of eligible HCC patients for anti-cytotoxic T-lymphocyte antigen 4 or anti-programmed death 1/programmed death-ligand 1 treatment

Subjects of 18 years or older (men and women)

Histologically confirmed advanced HCC

They are not eligible for surgical and/or locoregional therapies

Eastern Cooperative Oncology Group performance status of 0–1

They have progressive disease after surgical and/or locoregional therapies

Dose escalation phase: Child–Pugh score of 7 points or less. Cohort 5: Child–Pugh class B (B7–B8). For all other cohorts Child–Pugh score of 6 points or less

There is no history of autoimmune disease, any prior or current clinically significant ascites, or any history of hepatic encephalopathy

Abbreviation: HCC, hepatocellular cancer.